Available Brands
Did you find this information helpful?
Author Details
Written By
Vishishta
M.Sc Microbiology

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 14 Oct 2026 | 09:05 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
IXEKIZUMAB
Last updated on 14 Oct 2026 | 09:05 AM (IST)
IXEKIZUMAB
Molecule Overview
Ixekizumab is a lab-made antibody that helps calm an overactive immune response involved in certain inflammatory skin and joint conditions. It belongs to a class of medicines called IL-17A inhibitors, used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is a prescription-only, self-injectable medicine.
Medical Classification
Therapeutic Class: Targeted immunomodulator for inflammatory skin and joint conditions.
Pharmacological Class: Interleukin-17A (IL-17A) antagonist.
Drug Family: Humanized IgG4 monoclonal antibodies.
ATC Classification: L04AC13 (Ixekizumab).
Conditions Treated
Approved: Moderate-to-severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy; active psoriatic arthritis in adults; active ankylosing spondylitis in adults; and active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults.
Commonly used for: Patients with moderate-to-severe plaque psoriasis affecting quality of life, and patients with inflammatory joint and spine conditions not adequately controlled by other treatments.
Off-label use (only under medical guidance): Being studied in other IL-17-driven inflammatory conditions in clinical trials; use outside approved indications is a specialist decision.
Available Strengths & Dosage Forms
● Injection (prefilled syringe or autoinjector pen, subcutaneous): 80 mg/mL.
How the Molecule Works
Ixekizumab binds to and blocks a protein called interleukin-17A (IL-17A), a key inflammatory messenger that drives the excessive skin cell turnover seen in psoriasis and the joint/spine inflammation seen in psoriatic arthritis and ankylosing spondylitis. By neutralising IL-17A, ixekizumab helps reduce inflammation, skin plaques, and joint symptoms.
Dosage & Administration
Standard dose (plaque psoriasis): 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
Condition-wise dose (psoriatic arthritis, ankylosing spondylitis): 160 mg at Week 0, followed by 80 mg every 4 weeks; for non-radiographic axial spondyloarthritis, there is no separate starting dose — treatment is simply 80 mg every 4 weeks.
Route: Subcutaneous injection, self-administered after training, typically in the thigh, abdomen, or upper arm.
Missed dose: Take as soon as remembered, then resume the regular dosing schedule; don't double up.
Overdose: May increase the risk of known side effects such as infection; requires medical attention.
Side Effects
Common: Injection-site reactions, upper respiratory tract infections, nausea, and mild to moderate infections (including oral candidiasis and tinea infections).
Serious: Increased risk of serious infections, low white blood cell counts (neutropenia), and rare cases of inflammatory bowel disease (new-onset or worsening Crohn's disease or ulcerative colitis).
Emergency symptoms: Signs of serious infection (fever, chills, persistent cough), new or worsening abdominal pain with diarrhoea, or signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing).
Recovery advice: Testing for tuberculosis and hepatitis before starting, along with prompt reporting of any new infection symptoms, helps manage the infection risk associated with this type of immune-targeted therapy.
Warnings & Precautions
Pregnancy: Limited human data; used only if clearly needed, under medical guidance.
Breastfeeding: Ixekizumab has been detected in breast milk in animal studies; the benefits of breastfeeding should be weighed against the clinical need for treatment, with the treating doctor.
Liver disease: No formal studies conducted on hepatic impairment; used with routine monitoring.
Kidney disease: No formal studies conducted on renal impairment; used with routine monitoring.
Elderly: No significant differences in safety or efficacy observed between older and younger patients in trials, though used with routine monitoring.
Children: Approved for moderate-to-severe plaque psoriasis in children 6 years and older; not established for other indications in children.
Drug Interactions
● Live vaccines: should be avoided during treatment; patients should be brought up to date on vaccinations before starting.
● Other biologic immunosuppressants: combining with other biologic therapies is generally avoided due to increased infection risk, unless specifically directed by a specialist.
● Methotrexate and other conventional DMARDs: can be used alongside ixekizumab in psoriatic arthritis and other joint conditions, as clearance of ixekizumab is not significantly affected by these medicines.
● CYP450 substrate drugs: IL-17 inhibition can normalise CYP450 enzyme activity that may have been suppressed by chronic inflammation, potentially affecting levels of certain narrow-therapeutic-index drugs metabolised by these enzymes.
Monitoring Requirements
● Tuberculosis screening before starting treatment.
● Monitoring for signs of infection throughout treatment.
● Assessment for new or worsening gastrointestinal symptoms suggestive of inflammatory bowel disease.
● Periodic clinical review of skin/joint symptom response to guide ongoing treatment decisions.
Alternative Molecules
Secukinumab (another IL-17A inhibitor), Adalimumab, Etanercept (TNF blockers, different mechanism), Guselkumab, Risankizumab (IL-23 inhibitors, different mechanism).
● Plaque Psoriasis Medicines
● Psoriatic Arthritis Treatments
● IL-17 Inhibitors
FAQs
Q1.
It's used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
Q2.
As a subcutaneous injection, typically self-administered after training, following a specific starting schedule that varies by condition, then continuing every 4 weeks.
Q3.
Yes, like other immune-targeted biologics, it can increase susceptibility to infections, which is why screening (including for tuberculosis) is done before starting and monitoring continues throughout treatment.
Q4.
Yes, for moderate-to-severe plaque psoriasis in children 6 years and older; other indications are approved for adults only.
Q5.
Rare cases of new-onset or worsening Crohn's disease or ulcerative colitis have been reported with ixekizumab, so new or worsening gastrointestinal symptoms should be reported to the treating doctor.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






